Earlier we have found that in p53-deficient cells the expression of activated Ras attenuates the DNA damage-induced arrest in G1 and G2. In the present work we studied Ras-mediated effects on the G2 checkpoint in two human cell lines, MDAH041 immortalized fibroblasts and Saos-2 osteosarcoma cells. The transduction of the H-Ras mutants that retain certain functions (V12S35, V12G37, V12C40, retain the ability to activate Raf or RalGDS or PI3K, respectively) as well as the activated or dominant-negative mutants of RalA (V23 and N28, respectively) has revealed that the activation of Ras-RalGEFs-Ral pathway was responsible for the attenuation of the G2 arrest induced by ethyl-metane sulfonate (EMS) or doxorubicin. Noteworthy, the activated RalA V23N49 mutant, which cannot interact with RLIP76/RalBP1 protein, one of the best studied Ral effectors, retained the ability to attenuate the DNA damage-induced G2 arrest.
INTRODUCTION
The proteins of the Ras family, which include H-, K-and N-Ras, function as key regulators of the signal transduction pathways controlling cell proliferation, survival, migration, and differentiation (1) (2) (3) (4) (5) . Various extracellular signals reaching cell-surface receptors stimulate the conversion of the Ras proteins from the inactive GDP-bound to the active GTP-bound form.
In the GTP-bound form Ras stimulates downstream effectors, which, in turn, affect activities of numerous proteins, including the large group of transcription factors (1) (2) (3) (4) (5) .
Mutations that constitutively activate Ras proteins are characteristic of many human tumors. In fact, they are found in 95-98% of pancreatic cancers, 40-50% of colon and thyroid tumors, 25-30% of lung tumors, leukemias and some other malignancies (6) (7) (8) . Substantial experimental data indicate that such aberrant Ras activation plays a critical role in oncogenesis causing permanent stimulation of cell proliferation, increased cell motility, inhibition of apoptosis and angiogenesis (4, (9) (10) (11) (12) (13) (14) (15) , i.e. the features that are responsible for tumor growth and invasion (16) .
These effects are mediated mainly via three groups of Ras effectors: (i) Raf serine/threonine kinases (c-Raf-1, A-Raf, and B-Raf); (ii) PI3Ks 1 lipid kinases; and, (iii) RalGEFs for the small GTPases RalA and RalB (RalGDS, Rgl/Rsb2, Rgl2/Rlf, and RGL3) (1) (2) (3) (4) (5) 10, (17) (18) (19) (20) .
The Raf kinases phosphorylate and activate Mek1 and Mek2 dual specificity kinases, which, in turn, phosphorylate and activate Erk1/p44 and Erk2/p42 MAPKs playing key roles in the stimulation of cell division (21, 22) . Frequent occurrence in human melanomas and thyroid papillary cancers of either Ras or B-Raf mutations indicate that Raf activation can substitute the oncogenic effect of Ras activation in the course of development of some types of human tumors (23, 24) . Activation of the Raf-Erk pathway was also shown to be critical for the Ras-induced oncogenic transformation of rodent fibroblasts (25) (26) (27) (28) . PI3Ks phosphorylate inositol phospholipids that serve as signaling molecules regulating the activity of Akt/PKB protein kinases, GEFs for the Rho-family GTP-ases and some other proteins (29) (30) (31) . Stimulation of the PI3K-Akt pathway is thought to exert an anti-apoptotic effect (14, 31, 32) as well as reorganization of the actin cytoskeleton and activation of the lamellipodial activity (1, 30, 33) .
Although activated variants of the PI3K alone are unable to transform mouse NIH3T3 fibroblasts, they can do this in cooperation with the activated Raf (33) . Through the RalGEFs Ras stimulates the Ral proteins that can result in activation of the RLIP76/RalBP1 protein functioning as Cdc42/Rac-GAP and a transporter of amphilitic molecules, activation of PLD1, and alteration of the activity of a group of transcription factors (4, 17, 18) . These Ral activities are involved in the regulation of cell morphology and proliferation, receptor endocytosis and transport of xenobiotics (17, 18, 34) . Noteworthy, unlike in mouse fibroblasts, the activation of RalGEFs in human cells rather than the activation of Raf or PI3K plays a central role in the Ras-induced oncogenic transformation (19, 20) .
In addition to the stimulation of cell proliferation, motility, and inhibition of apoptosis, the expression of Ras oncoproteins causes genetic instability (35) (36) (37) (38) (39) (40) (41) representing the driving force for steadfast tumor progression (42, 43). We have found previously that the genetic instability can be connected in part with the inhibitory effects of Ras oncoproteins on the function of the DNA damage G1 and G2 cell cycle checkpoints (39). These Ras activities are especially notable in the cells showing dysfunction of the p53 tumor-suppressor, which is the most common feature of various human tumors. In particular, the p53 inactivation coupled with the expression of activated Ras almost completely abrogates EMS-induced G2 arrest in rat and human fibroblasts while each of these alterations alone have no notable effect on the function of the G2 checkpoint (39).
The goal of this work was to study possible mechanisms by which Ras oncoproteins can modulate the activity of the G2 cell cycle checkpoint in p53-deficient human cells. In particular, we decided to determine the involvement of different Ras effectors in the regulation of the G2-to-M transition in damaged cells. Also, we studied how the activated Ras and its effectors affect the activity of cyclin B/CDC2 kinase, which is believed to play a key role in the entering to mitosis (44-46). We present evidences indicating that activation of the Ras-Ral pathway interferes with the DNA damage-induced inactivation of cyclin B1/CDC2 and G2 cell cycle arrest that can contribute to genetic instability of neoplastic cells. To visualize cyclin B1 and CDC2 localization, cells were cultured on coverslips, fixed with ice cold methanol, incubated with anti-cyclin B1 and anti-CDC2 antibody (1:50) for 1 hour at room temperature, and then with FITC-and TRITCconjugated antibody for 1 hour at room temperature. After washing with PBS cells were incubated with 0.2µg/ml Hoechst for 10 min for nucleus staining, examined with fluorescent microscope and photographed with Kodak digital camera.
Immunofluorescence analysis --
Ral activity assay --Cells were incubated in serum-free media for 24 hours. Thirty minutes after stimulation with 10% FBS cells were lysed in RAB buffer (Upstate Biotechnology).
The amount of GTP-bound Ral was determined using Ral Activation Assay Kit (Upstate Biotechnology) according to the manufacturer's protocols.
Cyclin B1/CDC2 immunoprecipitation and kinase assay --Cells were synchronized by double thymidine block. Nine hours after releasing from the block cells were lyzed at 4°C in lysis buffer (50 mM Tris-HCl pH 7.4, 250 mM NaCl, 1mM EDTA, 50 mM NaF, 1mM DTT, 0.1% Triton X-100, 10 µM leupeptine, 100 µg/ml aprotinin). Lysates were incubated overnight at 4°C with anti-B1 antibodies and Protein G-Sepharose. The beads were pelleted at 14,000g, washed three times with lysis buffer and twice with kinase buffer (50 mM Tris-HCl pH 7.5, 250 mM NaCl, 10mM MgCl2, 2mM DTT, 40 mM в-glycerophosphate, 20mM p-nitrophenylphosphate, 0.1 mM sodium vanadate). The kinase activity of immunoprecipitated cyclin B1/CDC2 complex was assessed by its ability to phosphorylate histone H1-specific peptide using the CDC2 protein assay system (Promega) according to the manufacturer's protocols. Table) , and increased the number of mitoses in unsynchronized cell cultures exposed to EMS (Table) or doxorubicin ( Fig. 3) . At the same time, the other two lossof-function Ras mutants showing preferential ability to bind to PI3K or c-Raf (V12C40 and V12S35, respectively) practically did not affect the G2-to-M transition in damaged cells (Fig. 2, 3 , Table) . The differences in the activity of the mutants were revealed despite the fact that Western analysis demonstrated similar levels of V12, V12S35, V12G37, and V12C40 proteins in the corresponding MDAH041 and Saos-2 cell sublines ( Fig. 1) . Moreover, the V12S35 and 
RESULTS

Influence of various Ras mutants on the DNA damage-induced G2 cell cycle arrest
Influence of RalA mutants on the G2 cell cycle arrest in damaged cells
The activity of V12G37 Ras protein is generally ascribed to its ability to activate RalGEFs (17) . However, this Ras mutant retains the ability to interact with other proteins such as Rin1 One of the known effectors of activated Ral is RLIP76/RalBP1. The ability of this protein to bind to CDC2 and modulate its kinase activity (58) prompted us to test whether the effect of RalA on the G2 checkpoint is mediated through the Ral-RLIP76/RalBP1 interaction. For this purpose we used the RalA-V23N49 mutant, which cannot interact with the RLIP76/RalBP1 protein (50). The expression of RalA-V23N49 caused the effect similar to that of the RalA-V23
and Ras-V12G37, i.e. attenuation of the G2 arrest induced by exposure to EMS or doxorubicin (Fig. 3, 6 ) suggesting that the effect of RalA on the DNA damage-induced G2 checkpoint is independent of RLIP76/RalBP1. 
Ras-Ral signaling affects phosphorylation and activity of cyclin B/CDC2 in damaged cells
Since the function of cyclin B/CDC2 is considered as a major determinant responsible for entering to mitosis, we studied whether the expression of Ras and/or RalA mutants affects the activity of this kinase. It was found that treatment with EMS of synchronized MDAH041 cell cultures progressing through G2 caused about 2.5-fold decrease in cyclin B1/CDC2 kinase activity at the G2/M border, i.e. 9.5 hours after release from thymidine block (Fig. 7) . Expression of V12 and V12G37 Ras mutants abrogated the EMS-induced inhibition of cyclin B1/CDC2 kinase activity while V12S35 and V12C40 mutant proteins showed no such effect. Inhibition of Ral activity in the cells expressing the Ras-V12 protein by transduction of dominant-negative
RalA-N28 mutant restored the repressing effect of EMS on the cyclin B1/CDC2 kinase activity.
On the other hand, the expression of activated RalA-V23 mutant showed an effect similar to that caused by Ras V12 and V12G37 proteins, i.e. the lack of EMS-induced inhibition of cyclin B1/CDC2 kinase activity (Fig. 7) . This result suggests that the relaxation of DNA damage G2 checkpoint in cells with activated Ras-Ral pathway is connected with some changes in regulation of cyclin B1/CDC2 function leading to retention of its activity in damaged cells.
To learn more about the ways by which activation of Ras-Ral signaling affects the activity of cyclin B1/CDC2 kinase in cells with damaged DNA, we studied how the expression of H-Ras and RalA mutants influences in MDAH041 cell sublines (i) the levels of cyclin B1, CDC2 and, p21 Cip1/Waf1 and p27 Kip1 CKIs proteins; (ii) intracellular localization of cyclin B1 and CDC2 and their ability to form complex; and, (iii) inhibitory phosphorylation of CDC2 at Tyr15. Western analysis revealed no effect of Ras and RalA expression on the content of cyclin B1, CDC2 and CKIs proteins in the control and EMS-treated cells (Fig. 8A) . Also, immunoprecipitation with cyclin B1
antibody followed by staining with anti-CDC2 antibody failed to reveal any difference in cyclin B1/CDC2 complex formation between the original cells and their Ras-and/or RalA-expressing derivatives (Fig. 8B ). In addition, Ras and RalA expression produced no effect on the intracellular localization of cyclin B1 and CDC2 proteins in EMS-treated cells analyzed 9 hours after release from thymidine block, i.e. in late G2 and/or at the G2/M border (Fig. 9) . On the other hand, we found that the changes in Ras/RalA activity affect the phosphorylation of CDC2 at Tyr15, which represents common mechanism of cyclin B1/CDC2 kinase inhibition by various DNA damaging insults (60) (61) (62) (63) . In fact, expression of the Ras-V12G37 protein as well as activated RalA-V23 mutant attenuated the EMS-induced CDC2 phosphorylation (Fig 10) . The lack of the CDC2 phosphorylation at Tyr15 correlated well with the absence of G2/M arrest in the EMS-treated cells (Fig. 10B) . Abrogation in Ras-expressing cells of Ras-Ral signaling by transduction of dominant-negative RalA-N28 mutant restored the EMS-induced CDC2 phosphorylation at Tyr15 (Fig. 10A) that correlated with the restoration of function of DNA damage G2 checkpoint (Fig. 5, 6 ). In conclusion, our results reveal the ability of activated Ras oncogene to affect via the Ras-Ral signaling pathway the activity of cyclin B/CDC2 kinase and, as a result, to attenuate the DNA damage G2 checkpoint. This novel activity of Ras protein along with its known abilities to induce mutagenic reactive oxygen species (72, 73) also Table) . Cells were incubated in serum-free media for 24 hours. Thirty minutes after stimulation with 10% FCS cells were lyzed and the fraction of GTP-bound Ral was measured by its binding to effector protein RLIP76/RalBP1 using the Ral Activation Assay Kit (Upstate Biotechnology).
DISCUSSION
Total Ral protein expression was assayed in 1/20 of the lyzate. Cell cultures synchronized at G1/S border were lyzed 10 h after release from thymidine block. EMS (600 µg/ml) was added for 4 hours. Cyclin B1/CDC2 complexes were immunoprecipitated with anti-cyclin B1 antibodies and their CDC2 kinase activity was determined as described in Experimental Procedures. The summarized data of two experiments are presented. Expression of Ras-V12, Ras-V12G37 and RalA-V23 abrogated the EMSinduced decrease in cyclin B1/CDC2 kinase activity. The dominant-negative RalA-N28 mutant inhibited the effect of Ras-V12 on cyclin B1/CDC2 function. , p27 Kip1 protein levels (A) and cyclin B1/CDC2 complex formation (B).
(A) EMS (600 µg/ml) was added to unsynchronized MDAH041 cell cultures for 4 hours, then the cells were lyzed and Western analysis was performed as described in Experimental
Procedures. (B) Immunoprecipitation with antibodies to cyclin B1 followed by Western analysis with antibodies to CDC2 was performed as described in Experimental Procedures. a Determined by FACScan analysis 12 hours after release from double thymidine block as described in Experimental Procedures and Legend to Fig. 2 . EMS (600 µg/ml) was added 4 hours before the fixation. For each cell subline summarized data of two experiments are presented.
b EMS (600 µg/ml) was added 4 hours before the fixation. Summarized data of 2-3 experiments are presented. For each point 2000-5000 cells were scored. The bottom Table presents the morphometric parameters of various Saos-2 cell derivatives. Cell areas, dispersion and elongation indices were determined according to Dunn and Brown, J. Cell Sci., 1986, 108:1659-1667 (elongation characterizes the level of cell stretch and orientation; dispersion reflects the number of cell protrusions and grows up with an increase of their number and length). Briefly, cell microphotographs were obtained with digital camera, and cell contours were processed from files of DXF format using special program-macros for AutoCAD (TRACE for AutoCAD (created and kindly provided by M.Spivakov, Moscow University, Russia). In each case 60-70 cells were analysed.
The expression of H-Ras V12S35 and V12C40 partial loss-of-function mutants (interact with Raf and PI3K, respectively) caused prominent changes of cell morphology similar to that observed in cells expressing activated V12 H-Ras mutant. The V12G37 mutant retaining the ability to bind to Ral-GDS, but not to Raf and PI3K, caused minor changes in cell shape. 
Phospho-p44 ERK
Phospho-p42 ERK
Western analysis of subconfluent cell cultures grown in complete medium was performed as described in Experimental Procedures using the E10 monoclonal antibody specific to p44/p42 ERKs phosphorylated at Thr202/Tyr204 (obtained from Cell Signaling Technology). The most prominent ERK phosphorylation was observed in cells expressing V12 and V12S35 mutants which are able to bind to c-Raf. Cells expressing Ras-V12C40 or Ras-V12G37 mutants (interact with PI3K and RalGDS, respectively) showed no or moderate increase in content of phospho-ERKs.
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